Overview

Influence of Lipid Lowering on Impaired Coronary Flow

Status:
Recruiting

Trial end date:
2025-09-30

Target enrollment:
0

Participant gender:
All

Summary

This study assess in patients with stable chest pain and coronary artery disease (CAD) determined by coronary CTA whether cholesterol lowering with regression of coronary adverse plaque characteristics is associated with recovery of impaired flow

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Aarhus University Hospital

Collaborator:

HeartFlow, Inc.

Treatments:

Atorvastatin
Ezetimibe
Rosuvastatin Calcium

Criteria

Inclusion Criteria: Age ≥35 y, symptoms suggestive of stable CAD, No pre-CTA known CAD, at
least one leasion with FFRct <0.81, sinus rhythm, LDL cholesterol >2.0 mM, statin use >2
months, life expentancy > 3 years, signed informed consent -

Exclusion Criteria:

Known CAD, poor CTA image quality inadequiate for FFRct analysis (determined by corelab),
BMI >40, allergy to ionidated contrast, pregnancy, significant CAD in the left main or
proximal coronary segments, referral to invasive cath., statin intolerance

-